Sponsored by: Safeguarding Scientific Value: Why Sample Management and Data Quality Are Non-Negotiable in Clinical Research

What happens when sample integrity or data quality breaks down? The consequences can ripple across an entire study. This presentation examines the critical link between specimen management, data reliability, and regulatory confidence, offering insights into how organizations can reduce risk and preserve the scientific value of every patient sample.

Sponsored by: No Sample Left Behind: Rewiring Biospecimen Management for Quality, Speed, and Visibility 

Session Overview
A joint case study presentation between Pfizer and TruTechnologies, highlighting how Pfizer transformed a manual, paper-based biological sample management process into a quality award-winning digital model. The Operational Challenge Managing sample logistics across large-scale clinical trials involving hundreds of sites and more than one million samples processed annually through a central hub created a highly complex operation with significant quality risk exposure. In vaccine trials, every biospecimen is more than a tube. It is a potential data point, a quality obligation, and often an irreplaceable contribution from a participant. Yet for years, critical sample information depended on paper forms, delayed visibility, manual reconciliation, and email-based follow-up.

The Solution & Approach
A cross-functional team across Pfizer partnered with TruTechnologies to deploy the TruLab mobile application (branded internally as "Find My Sample") directly at clinical sites. By adopting a "Quality: Think Differently" mindset, Pfizer converted biospecimen management from a retrospective reconciliation activity into a prospective quality oversight capability. The transition from paper forms to live dashboarding gave the team unprecedented line of sight into sample collection and shipping, enabling them to address execution issues early, avoid lost samples, and accurately forecast downstream laboratory workflows.

Measurable Results
The implementation delivered significant operational improvements and quality wins across Pfizer's vaccine trials. This included an over 90% reduction in unresolvable sample discrepancies, virtual elimination of Good Documentation Practice (GDP) paper lapses, a 98% drop in paper archiving time, and a greater than 95% reduction in query-related emails between sites, sample logistics, and study managers. The approach has since expanded across hundreds of clinical sites and a large volume of vaccines biospecimens, demonstrating that digital biospecimen oversight can be implemented at operational scale.

Key Audience Takeaways
The session offers practical strategies for managing digital rollouts across global sites, eliminating paper-based documentation errors to uphold GCP standards, and protecting trial timelines while keeping site burden low. Attendees will leave with a practical blueprint for moving biospecimen management from retrospective sample chasing to proactive, digitally enabled quality oversight.